Squaring up the health economics of PCSK9 monoclonal antibodies 'down under'
- PMID: 29887280
- DOI: 10.1016/j.ijcard.2018.06.003
Squaring up the health economics of PCSK9 monoclonal antibodies 'down under'
Comment on
-
The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective.Int J Cardiol. 2018 Sep 15;267:183-187. doi: 10.1016/j.ijcard.2018.04.122. Epub 2018 Apr 26. Int J Cardiol. 2018. PMID: 29731350
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous